Your session is about to expire
← Back to Search
Gene Therapy
Gene Therapy for Retinoschisis (LIGHTHOUSE Trial)
Phase 1 & 2
Recruiting
Research Sponsored by Atsena Therapeutics Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline to week 52
Awards & highlights
Summary
This trial will test the safety of ATSN-201, a one-time eye injection, in males aged 6 and older with a specific eye condition called XLRS.
Who is the study for?
This trial is for male patients with X-linked retinoschisis (XLRS) due to RS1 mutations. Adults must be between 18 and 64 years old, while children should be aged 6 to under 18. Participants need a specific level of vision clarity. Those who've had previous eye gene therapy or certain eye conditions/surgeries are excluded.
What is being tested?
The study tests the safety and effects of ATSN-201, a gene therapy for males with XLRS. It will involve different age groups (cohorts) to assess how well they tolerate this potential new treatment.
What are the potential side effects?
While not explicitly listed, side effects may include typical risks associated with gene therapies such as immune reactions, discomfort at injection site, and potential worsening of vision or other ocular issues.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ from baseline to week 52
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline to week 52
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Safety and tolerability as assessed by dose-limiting toxicities and treatment-emergent adverse events
Secondary study objectives
Macular structure as assessed by fundus autofluorescence
Macular structure as assessed by spectral domain optical coherence tomography
Subject-reported visual function as assessed by the CVAQC in pediatric subjects
+7 moreTrial Design
7Treatment groups
Experimental Treatment
Active Control
Group I: Cohort 5, PediatricExperimental Treatment1 Intervention
ATSN-201 at High Volume
Group II: Cohort 4, Low DoseExperimental Treatment1 Intervention
ATSN-201 at Low Volume
Group III: Cohort 4, High DoseExperimental Treatment1 Intervention
ATSN-201 at High Volume
Group IV: Cohort 3Experimental Treatment1 Intervention
ATSN-201 at Mid Dose
Group V: Cohort 2Experimental Treatment1 Intervention
ATSN-201 at High Dose
Group VI: Cohort 1Experimental Treatment1 Intervention
ATSN-201 at Low Dose
Group VII: Cohort 4, ControlActive Control1 Intervention
Find a Location
Who is running the clinical trial?
Atsena Therapeutics Inc.Lead Sponsor
1 Previous Clinical Trials
15 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I haven't had eye surgery or laser treatment in the past 6 months and don't plan any in the next year.I have an eye condition that could worsen with certain eye injections.I am at least 18 years old for Cohorts 1-3, or between 6 and 17 years old for Cohort 4.I am a male diagnosed with XLRS due to RS1 gene mutations.
Research Study Groups:
This trial has the following groups:- Group 1: Cohort 4, Control
- Group 2: Cohort 4, Low Dose
- Group 3: Cohort 5, Pediatric
- Group 4: Cohort 3
- Group 5: Cohort 4, High Dose
- Group 6: Cohort 1
- Group 7: Cohort 2
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger